Glimepiride Accord Healthcare

Glimepiride Accord Healthcare is an oral tablet containing the active ingredient glimepiride, a sulfonylurea antidiabetic agent. The product is manufactured by Accord Healthcare and marketed in the European Union. While the specific tablet strength and dosage form are not disclosed in the source data, the medication is classified as a prescription‑only (Rx) drug intended for the management of blood glucose in adults with type 2 diabetes mellitus.

Glimepiride Accord Healthcare is prescribed primarily for the oral management of type 2 diabetes mellitus.

- As monotherapy in patients whose diet and exercise alone do not achieve glycemic control. - In combination with other oral antidiabetic agents (e.g., metformin) when additional glucose lowering is needed. - As part of a comprehensive diabetes care plan that includes diet, physical activity, and regular monitoring. - For adults with established type 2 diabetes to improve fasting and post‑prandial blood glucose levels.

The safety profile of glimepiride includes both common, generally mild reactions and rare but serious adverse events.

Common: - Low blood sugar (hypoglycemia), especially when meals are missed or dosing is excessive. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as rash, itching, or swelling. - Hepatic dysfunction indicated by elevated liver enzymes. - Hematologic abnormalities like leukopenia or thrombocytopenia.

Before initiating glimepiride, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function, as impairment can increase drug exposure. - Review patient history for prior sulfonylurea hypersensitivity or severe hypoglycemia. - Use caution in elderly patients who may be more susceptible to low blood sugar. - Avoid use during pregnancy or breastfeeding unless benefits outweigh risks. - Monitor blood glucose regularly during dose adjustments. - Educate patients on recognizing and managing hypoglycemia symptoms.

Glimepiride may interact with other medicines, altering its effectiveness or safety profile.

Avoid: - Concurrent use with other sulfonylureas or insulin, which can markedly increase hypoglycemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride plasma concentrations. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may affect glucose tolerance. - Antidepressants such as SSRIs that have been reported to influence blood sugar control.